Cat. No. 3269
Chemical Name: 2-(5-Chloro-2-fluorophenyl)-4-[(4-p
Biological ActivityPotent, orally active ATP-competitive transforming growth factor-β receptor 1 (TGF-βRI) inhibitor (IC50 = 49 nM). Displays > 100-fold and > 17-fold selectivity over TGF-βRII and other common kinases respectively. Exhibits anti-inflammatory and antitumor activity. Also promotes an antiglioma immune response. Ameliorates germinal matrix hemorrhage-induced neurological deficits in neonatal rats.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Manaenko et al (2014) Inhibition of transforming growth factor-β attenuates brain injury and neurological deficits in a rat model of germinal matrix hemorrhage. Stroke 45 828. PMID: 24425124.
Kapoun et al (2006) Transforming growth factor-β receptor type I receptor (TGFβRI) kinase activity but not p38 activation is required for TGFβRI-induced myofibroblast differentiation and profibrotic gene expression. Mol.Pharmacol. 70 518. PMID: 16707625.
Leung et al (2006) Effect of transforming growth factor-β receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J.Pharmacol.Exp.Ther. 319 586. PMID: 16888081.
Uhl et al (2004) SD-208, a novel transforming growth factor β feceptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogeneicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64 7954. PMID: 15520202.
If you know of a relevant reference for SD 208 please let us know.
Citations are publications that use Tocris products. Selected citations for SD 208 include:
Li and Gotlieb (2011) Transforming growth factor-β regulates the growth of valve interstitial cells in vitro. Am J Pathol 179 1746. PMID: 21851806.
Nistala et al (2010) Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. PLoS One 19 4790. PMID: 20871099.
Do you know of a great paper that uses SD 208 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SD 208, supplier, Potent, ATP-competitive, TGF-βRI, TGF-β, TGF-betaRI, TGFbRI, TGFbR1, tgf-b1inhibitors, inhibits, Transforming, Growth, Factors, Beta, Receptors, TGF-beta, Serine/Threonine, Kinases, RSTKs, SD208, Tocris Bioscience, TGF-β Receptor Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective ALK2 inhibitorLDN 212854
Potent bone morphogenetic protein type I (ALK) inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.